
Galaxy Medicare IPO Listing at 0% Premium at ₹54 Per Share
Updated: 17 Sept 2025 • 3:59 pm
Posted by:

Check Experts’ Verdicts on Galaxy Medicare Limited
Galaxy Medicare IPO Listing: The Galaxy Medicare IPO was subscribed 1.83 times as of its closing. In this subscription, qualified institutional buyers (QIBs) received 1.00 times the allocation, and non-institutional investors (NIIs) received 1.48 times the allocation. The retail quota of the issue was subscribed to 55.86%. Before delving deeper into the topic, go through the details of the Galaxy Medicare IPO.
Galaxy Medicare IPO Listing
On the NSE and SME platform, shares are listed at ₹54, reflecting a premium of 0% against the issue price of ₹54 per Share.
Galaxy Medicare IPO Details
It is a bookbuilding IPO of ₹22.31 crore, comprising a fresh issue of 0.33 crore shares and offer for sale of 0.08 crore shares. The problem will be listed on NSE and SME on its tentative listing date, 17th September 2025. The Galaxy Medicare IPO date is fixed between 10th September 2025 and 12th September 2025. The face value of Galaxy Medicare IPO shares stands at ₹10 per share, and the IPO price is set at ₹51.00 to ₹54.00 per share.
| IPO Open Date | 10th September 2025 |
| IPO Close Date | 12th September 2025 |
| IPO Allotment Date | 15th September 2025 |
| Refund Initiation | 16th September 2025 |
| Issue Size | 41,32,000 shares(aggregating up to ₹22.31 Cr) |
| Fresh Issue | 31,00,000 shares(aggregating up to ₹16.74 Cr) |
| Offer for Sale | 8,24,000 shares of ₹10(aggregating up to ₹4.45 Cr) |
| Face Value | ₹10 per share |
| Lot Size | 2,000 shares |
| Issue Price Band | ₹51.00 to ₹54.00 per share |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE & SME |
| Listing Date | 17th September 2025 |
About Galaxy Medicare Limited
Galaxy Medicare was established in July 1992. Galaxy Medicare Limited manufactures and exports medical devices, POP bandages, and surgical dressings in India. The company manufactures these products using premium-grade raw materials that are procured from the authentic vendors of the market. The company specialises in various products, including surgical dressings, plaster of Paris bandages, adhesive tapes, compression bandages, and wound care solutions. Their offerings meet diverse medical needs, including gauze products and orthopaedic items.
Galaxy Medicare Limited Financials
The company’s financial analysis is crucial before applying for the Galaxy Medicare IPO. Refer to the table to learn about Galaxy Medicare Limited’s financials.
| Year Ended | 31st March 2025 (in cr.) | 31st March 2024 (in cr.) | 31st March 2023 (in Cr) |
| Assets | 31.49 | 32.53 | 32.31 |
| Revenue | 40.27 | 36.94 | 32.03 |
| Profit After Tax | 3.37 | 3.71 | 1.57 |
| EBITDA | 4.58 | 5.26 | 3.14 |
| Net Worth | 18.36 | 15.54 | 11.94 |
| Reserve and surplus | 12.29 | 9.51 | 14.78 |
| Total Borrowing | 4.61 | 8.12 | 9.15 |
Explanation
Galaxy Medicare Limited’s revenue increased by 9% from ₹36.94 crore in March 2023 to ₹ 40.27 crore in March 2024. Moreover, the company’s PAT dropped by 9% from ₹3.71 crores to ₹3.37 crores.
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2025
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Galaxy Medicare IPO GMP & Review: Apply or Avoid?
Recent Articles
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Recent Posts
IKIO Technologies Analyst Review May 2026
Kaka Industries Q4 FY26 Results: PAT Rs 1.5 Cr, Revenue Rs 22 Crore
Bajaj Housing Finance Analyst Review May 2026
Zydus Wellness Q4 FY26 Results: PAT Rs 162 Cr, Revenue Rs 1,485 Crore
Kiaasa Retail Q4 FY26 Results: PAT Rs 17 Cr, Revenue Rs 249 Crore
Popular this week
IKIO Technologies Analyst Review May 2026
Kaka Industries Q4 FY26 Results: PAT Rs 1.5 Cr, Revenue Rs 22 Crore
Bajaj Housing Finance Analyst Review May 2026
Zydus Wellness Q4 FY26 Results: PAT Rs 162 Cr, Revenue Rs 1,485 Crore
Kiaasa Retail Q4 FY26 Results: PAT Rs 17 Cr, Revenue Rs 249 Crore

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
